EANM enabling guide: how to improve the accessibility of clinical dosimetry

Jonathan Gear; Caroline Stokke; Christelle Terwinghe; Silvano Gnesin; Mattias Sandström; Johannes Tran-Gia; Marta Cremonesi; Francesco Cicone; Fredrik Verburg; Roland Hustinx; Luca Giovanella; Ken Herrmann; Pablo Minguez Gabiña

doi:10.1007/s00259-023-06226-z

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Jonathan Gear^*
, Caroline Stokke
, Christelle Terwinghe
, Silvano Gnesin
, Mattias Sandström
, Johannes Tran-Gia
, Marta Cremonesi
, Francesco Cicone
, Fredrik Verburg
, Roland Hustinx
, Luca Giovanella
, Ken Herrmann
, Pablo Minguez Gabiña

^*Corresponding author for this work

Radiology & Nuclear Medicine

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

15 Downloads (Pure)

Abstract

Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [¹³¹I]-NaI for benign thyroid disorders, [¹⁷⁷Lu]-DOTATATE and ¹³¹I-mIBG for neuroendocrine tumours and [⁹⁰Y]-microspheres for unresectable hepatic carcinoma.

Original language	English
Pages (from-to)	1861-1868
Number of pages	8
Journal	European Journal of Nuclear Medicine and Molecular Imaging
Volume	50
Issue number	7
DOIs	https://doi.org/10.1007/s00259-023-06226-z
Publication status	Published - Jun 2023

Bibliographical note

Funding Information:
KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, all outside the submitted work. LG reports personal fees from Roche Diagnostics and SNIBE for advisory board participation, and research support from Roche Diagnostics., all outside the submitted work.

NHS funding was provided to the NIHR Biomedical
Research Centre at The Royal Marsden and the ICR.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Access to Document

10.1007/s00259-023-06226-zLicence: CC BY

EANM enabling guide how to improve the accessibility of clinical dosimetryFinal published version, 466 KBLicence: CC BY

Cite this

Gear, J., Stokke, C., Terwinghe, C., Gnesin, S., Sandström, M., Tran-Gia, J., Cremonesi, M., Cicone, F., Verburg, F., Hustinx, R., Giovanella, L., Herrmann, K., & Gabiña, P. M. (2023). EANM enabling guide: how to improve the accessibility of clinical dosimetry. European Journal of Nuclear Medicine and Molecular Imaging, 50(7), 1861-1868. https://doi.org/10.1007/s00259-023-06226-z

@article{eb6b2d8a1f2f4781925fbb5c8ead79b3,

title = "EANM enabling guide: how to improve the accessibility of clinical dosimetry",

abstract = "Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [131I]-NaI for benign thyroid disorders, [177Lu]-DOTATATE and 131I-mIBG for neuroendocrine tumours and [90Y]-microspheres for unresectable hepatic carcinoma.",

author = "Jonathan Gear and Caroline Stokke and Christelle Terwinghe and Silvano Gnesin and Mattias Sandstr{\"o}m and Johannes Tran-Gia and Marta Cremonesi and Francesco Cicone and Fredrik Verburg and Roland Hustinx and Luca Giovanella and Ken Herrmann and Gabi{\~n}a, \{Pablo Minguez\}",

note = "Funding Information: KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, all outside the submitted work. LG reports personal fees from Roche Diagnostics and SNIBE for advisory board participation, and research support from Roche Diagnostics., all outside the submitted work. NHS funding was provided to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. Publisher Copyright: {\textcopyright} 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2023",

month = jun,

doi = "10.1007/s00259-023-06226-z",

language = "English",

volume = "50",

pages = "1861--1868",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

number = "7",

}

Gear, J, Stokke, C, Terwinghe, C, Gnesin, S, Sandström, M, Tran-Gia, J, Cremonesi, M, Cicone, F, Verburg, F, Hustinx, R, Giovanella, L, Herrmann, K & Gabiña, PM 2023, 'EANM enabling guide: how to improve the accessibility of clinical dosimetry', European Journal of Nuclear Medicine and Molecular Imaging, vol. 50, no. 7, pp. 1861-1868. https://doi.org/10.1007/s00259-023-06226-z

TY - JOUR

T1 - EANM enabling guide

T2 - how to improve the accessibility of clinical dosimetry

AU - Gear, Jonathan

AU - Stokke, Caroline

AU - Terwinghe, Christelle

AU - Gnesin, Silvano

AU - Sandström, Mattias

AU - Tran-Gia, Johannes

AU - Cremonesi, Marta

AU - Cicone, Francesco

AU - Verburg, Fredrik

AU - Hustinx, Roland

AU - Giovanella, Luca

AU - Herrmann, Ken

AU - Gabiña, Pablo Minguez

N1 - Funding Information: KH reports personal fees from Bayer, personal fees and other from Sofie Biosciences, personal fees from SIRTEX, non-financial support from ABX, personal fees from Adacap, personal fees from Curium, personal fees from Endocyte, grants and personal fees from BTG, personal fees from IPSEN, personal fees from Siemens Healthineers, personal fees from GE Healthcare, personal fees from Amgen, personal fees from Novartis, personal fees from ymabs, all outside the submitted work. LG reports personal fees from Roche Diagnostics and SNIBE for advisory board participation, and research support from Roche Diagnostics., all outside the submitted work. NHS funding was provided to the NIHR Biomedical Research Centre at The Royal Marsden and the ICR. Publisher Copyright: © 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2023/6

Y1 - 2023/6

N2 - Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [131I]-NaI for benign thyroid disorders, [177Lu]-DOTATATE and 131I-mIBG for neuroendocrine tumours and [90Y]-microspheres for unresectable hepatic carcinoma.

AB - Dosimetry can be a useful tool for personalization of molecular radiotherapy (MRT) procedures, enabling the continuous development of theranostic concepts. However, the additional resource requirements are often seen as a barrier to implementation. This guide discusses the requirements for dosimetry and demonstrates how a dosimetry regimen can be tailored to the available facilities of a centre. The aim is to help centres wishing to initiate a dosimetry service but may not have the experience or resources of some of the more established therapy and dosimetry centres. The multidisciplinary approach and different personnel requirements are discussed and key equipment reviewed example protocols demonstrating these factors are given in the supplementary material for the main therapies carried out in nuclear medicine, including [131I]-NaI for benign thyroid disorders, [177Lu]-DOTATATE and 131I-mIBG for neuroendocrine tumours and [90Y]-microspheres for unresectable hepatic carcinoma.

UR - https://www.scopus.com/pages/publications/85153212204

U2 - 10.1007/s00259-023-06226-z

DO - 10.1007/s00259-023-06226-z

M3 - Article

C2 - 37086275

AN - SCOPUS:85153212204

SN - 1619-7070

VL - 50

SP - 1861

EP - 1868

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

IS - 7

ER -

EANM enabling guide: how to improve the accessibility of clinical dosimetry

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this